The nation of Zimbabwe has declined a significant American health deal valued at 367 million US dollars (272 million pounds) spanning five years due to Washington's demand for confidential information.
This move became public following a official document from December was disclosed, indicating that President Emmerson Mnangagwa felt the agreement was "lopsided".
A government spokesman later clarified that the United States was demanding access to health data for research and commercial gain while refused to share the resulting advantages from future vaccines.
"We must now begin the difficult and regrettable process of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for continued dialogue to secure a agreement suitable to both sides so the country's critical HIV treatment initiative can proceed.
Broader Context
This rejection comes after a similar case in Kenya, where a high court halted a similar deal with the US following concerns were raised about the safety of Kenyans' health data.
After resuming office last year, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the US government, but Trump stated its spending was "inefficient" and his administration was seeking government-to-government deals to enhance openness and responsibility.
According to reports, Sixteen African countries have so far agreed to similar health pacts, representing more than $18.3bn in committed funds.
Specifics of the Declined Deal
The funds for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation would have delivered significant benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently on HIV treatment through US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information for a long time, with no equivalent promise of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that provided information," Mangwana explained.
"Effectively, our nation would provide the basic resources for scientific discovery with no certainty that the final treatments would be accessible to our citizens if a new health crisis arise."
National Interest and Global Health
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were disrupting structures previously set up through the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing scheme designed to deal with future pandemics.
"This mechanism is designed to ensure that when a nation provides its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the resources to create them."
Zimbabwe's reservations over the US deal "are not meant as anti-American sentiment," he added.
"We encourage continued dialogue with our American counterparts on how future co-operation might be structured in a manner that respects the independence and interests of both nations."
Health Experts Response
A leading public health body expressed it acknowledged the government's concerns, but suggested that talks need to persist considering a large portion of the nation's HIV programmes relied on external financing.
"If technical issues exist, including those relating to information security or agreement terms, these can often be addressed via technical clarification and negotiated safeguards," the group said.
The halted deal underscores the complex tensions between receiving vital foreign assistance and protecting national sovereignty in an ever more data-driven world.